Archive for Publications

PHASE I OPEN-LABEL STUDY EVALUATING THE SAFETY, PHARMACOKINETICS, AND PRELIMINARY EFFICACY OF DILPACIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS

PHASE I STUDY OF 2- OR 3-WEEK DOSING OF TELISOTUZUMAB VEDOTIN, AN ANTIBODY–DRUG CONJUGATE TARGETING C-MET, MONOTHERAPY IN PATIENTS WITH ADVANCED NON–SMALL CELL LUNG CARCINOMA

A PHASE 1B STUDY OF TELISOTUZUMAB VEDOTIN IN COMBINATION WITH NIVOLUMAB IN PATIENTS WITH NSCLC

Telisotuzumab vedotin (Teliso-V) is an antic-Met–directed antibody-drug conjugate that has exhibited antitumor activity as monotherapy in NSCLC…

CASE REPORT: MARKED SURVIVAL ADVANTAGE OF TWO COLORECTAL CANCER PATIENTS WITH LIVER METASTASES TREATED WITH VIGIL AND FOLFOX-6

Colorectal cancer is the third most diagnosed cancer in the United States. Five-year survival rates remain low and many patients will develop liver metastasis….

A PHASE 1B STUDY OF TELISOTUZUMAB VEDOTIN IN COMBINATION WITH NIVOLUMAB IN PATIENTS WITH NSCLC

Telisotuzumab vedotin (Teliso-V) is an antic-Met–directed antibody-drug conjugate that has exhibited antitumor activity as monotherapy in NSCLC. Its potential activity combined with programmed cell death protein-1 inhibitors has not been previously evaluated.

MAXIMUM TOLERATED DOSE AND ANTI-TUMOR ACTIVITY OF INTRAPERITONEAL CANTRIXIL (TRX-E-002-1)

Cantrixil is a novel third-generation benzopyran molecule, with potent cytotoxicity against chemoresistant ovarian cancer stem cells and chemosensitive ovarian cancer cell lines. The aims of this Phase I study were to define the…

PIRTOBRUTINIB IN RELAPSED OR REFRACTORY B-CELL MALIGNANCIES (BRUIN): A PHASE 1/2 STUDY

Covalent Bruton’s tyrosine kinase (BTK) inhibitors are efficacious in multiple B-cell malignancies, but patients discontinue these agents due to resistance and intolerance…

EFFECTS OF ROVALPITUZUMAB TESIRINE ON VENTRICULAR REPOLARIZATION IN PATIENTS WITH SMALL-CELL LUNG CANCER

Small cell lung cancer (SCLC) is a leading cause of cancer death worldwide, with few treatment options. Rovalpituzumab tesirine (Rova-T) is an antibody-drug conjugate that targets delta-like 3 on SCLC cells to deliver a…

ENTRECTINIB IN PATIENTS WITH ADVANCED OR METASTATIC NTRK FUSION-POSITIVE SOLID TUMOURS: INTEGRATED ANALYSIS OF THREE PHASE 1–2 TRIALS

Entrectinib is a potent inhibitor of tropomyosin receptor kinase (TRK) A, B, and C, which has been shown to have anti-tumour activity against NTRK gene fusion-positive solid tumours, including…

LONG-TERM FOLLOW-UP OF PHASE 2A TRIAL RESULTS INVOLVING ADVANCED OVARIAN CANCER PATIENTS TREATED WITH VIGIL® IN FRONTLINE MAINTENANCE